Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor

Positron emission tomography (PET) is widely available and its application with 2-[ 18 F] fluoro-2-deoxy- d -glucose ( 18 F-FDG) in oncology has become one of the standard imaging modalities in diagnosing and staging of tumors, and monitoring the therapeutic efficacy in hepatic malignancies. Recentl...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology 2014-01, Vol.49 (1), p.46-56
Main Authors: Tsurusaki, Masakatsu, Okada, Masahiko, Kuroda, Hiroyuki, Matsuki, Mitsuru, Ishii, Kazunari, Murakami, Takamichi
Format: Article
Language:English
Subjects:
Abdominal Surgery
Cancer
Carcinoma, Hepatocellular - diagnostic imaging
Carcinoma, Hepatocellular - therapy
Care and treatment
Cholangiocarcinoma - diagnostic imaging
Cholangiocarcinoma - therapy
Colorectal Surgery
Dextrose
Fluorodeoxyglucose F18
Gastroenterology
Glucose
Health aspects
Hepatology
Humans
Liver
Liver Neoplasms - diagnostic imaging
Liver Neoplasms - secondary
Liver Neoplasms - therapy
Medical care
Medicine
Medicine & Public Health
Metastasis
Multimodal Imaging - methods
Neoplasm, Residual
PET imaging
Positron-Emission Tomography - methods
Quality management
Radiopharmaceuticals
Review
Surgical Oncology
Tomography, X-Ray Computed
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Positron emission tomography (PET) is widely available and its application with 2-[ 18 F] fluoro-2-deoxy- d -glucose ( 18 F-FDG) in oncology has become one of the standard imaging modalities in diagnosing and staging of tumors, and monitoring the therapeutic efficacy in hepatic malignancies. Recently, investigators have measured glucose utilization in liver tumors using 18 F-FDG and positron emission tomography/computer tomography (PET/CT) in order to establish a diagnosis of tumors, assess their biologic characteristics and predict therapeutic effects on hepatic malignancies. The PET/CT with 18 F-FDG may further enhance the hepatic malignancy diagnostic algorithm by accurate diagnosis, staging, restaging and evaluating its biological characteristics, which can benefit the patients suffering from primary and metastatic hepatic tumors such as hepatocellular carcinoma (HCC), cholangiocarcinoma (CCC), and metastatic liver tumor.
ISSN:0944-1174
1435-5922
DOI:10.1007/s00535-013-0790-5